Related Experiment Video
Updated: Feb 7, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma
Hao Huang1, Yang Liu1, Quan-de Lin1
1Department of Hematology, Cancer hospital of Henan province , The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Recombinant human endostatin (rhES) can inhibit multiple myeloma, while its clinical efficacy in treating relapsed refractory multiple myeloma (RRMM) has not been assessed. One hundred and eleven RRMM patients were treated with four different regimens: combination of VD (velcade+dexamethasone) and rhES (n = 25), Thalidomide (Tha) and VD (VTD, n = 22) combination, rhES and conventional chemotherapy combination (n = 32), and combination of conventional chemotherapy and Tha (n = 32). Significant differences were found in progression-free survival (PFS) between rhES combination groups and conventional chemotherapy combination groups. No statistical difference was found in overall response rate, overall survival or incidences of adverse effects. The combination of rhES with VD or conventional chemotherapy is active in patients with RRMM and prolongs the PFS to improve the quality of life.
Related Concept Videos
Recombinant DNA
Naturalistic Observations
Viral Recombination
Homologous Recombination
Multiple Allele Traits
Overview of Transposition and Recombination

